Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer

Table 1 Efficacy of the two treatment approaches, n (%)

Groups	CR	PR	SD	PD	Clinical efficacy, %	Disease control rate, %
Observation group, n = 30	7 (23.33)	15 (50.00)	6 (20.00)	2 (6.67)	73.33	93.33
Control group, n = 30	5 (16.67)	11 (36.67)	8 (26.67)	6 (20.00)	53.33	80.00
χ2 value					15.521	5.660
P value					0.001	0.041

Clinical efficacy = complete remission + partial remission; Disease control rate = complete remission + partial remission + stable disease. CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: progressive disease.

Table 2 Comparison of alpha-fetoprotein between the two groups before and after the treatment (mean ± SD, ng/mL)

Groups	Before the treatment	After the treatment
Observation group, n = 30	621.07 ± 154.76	289.06 ± 76.21
Control group, n = 30	609.76 ± 145.69	365.01 ± 73.11
t value	1.024	6.843
P value	0.237	0.034

Table 3 Incidence of adverse reactions in the two groups after the treatment, n (%)

Groups	Nausea and vomiting	Pain	Fever
Observation group, n = 30	9 (30.00)	21 (70.00)	11 (36.67)
Control group, n = 30	19 (63.33)	22 (73.33)	12 (40.00)
χ2 value	6.421	0.245	0.312
P value	0.035	0.543	0.564